Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan.
J Oncol. 2010;2010:723798. doi: 10.1155/2010/723798. Epub 2010 May 5.
Solid tumors are known to recruit new blood vessels to support their growth. Therefore, unique molecules expressed on tumor endothelial cells can function as targets for the antiangiogenic therapy of cancer. Current efforts are focusing on developing therapeutic agents capable of specifically targeting cancer cells and tumor-associated microenvironments including tumor blood vessels. These therapies hold the promise of high efficacy and low toxicity. One recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics is to encapsulate anticancer drugs into targeting liposomes that bind to the cell surface receptors expressed on tumor-associated endothelial cells. These anti-angiogenic drug delivery systems could be used to target both tumor blood vessels as well as the tumor cells, themselves. This article reviews the mechanisms and advantages of various present and potential methods using peptide-conjugated liposomes to specifically destroy tumor blood vessels in anticancer therapy.
实体瘤已知会募集新的血管来支持其生长。因此,肿瘤内皮细胞上表达的独特分子可以作为癌症抗血管生成治疗的靶点。目前的努力重点是开发能够特异性靶向癌细胞和肿瘤相关微环境(包括肿瘤血管)的治疗剂。这些疗法有望具有高效和低毒性。提高传统化疗药物治疗效果的一种公认策略是将抗癌药物包封入靶向脂质体中,这些脂质体与肿瘤相关内皮细胞表面表达的细胞表面受体结合。这些抗血管生成药物传递系统可用于靶向肿瘤血管和肿瘤细胞本身。本文综述了使用肽偶联脂质体特异性破坏抗癌治疗中肿瘤血管的各种现有和潜在方法的机制和优势。